Loading...
Mounting evidence suggests that thiopurine use for treatment of Crohn disease is associated with increased risks for nonmelanoma skin cancer (NMSC) and lymphoma. Evidence is less clear on whether use of tumor necrosis factor blockers by themselves increases these risks, although results of individual studies have shown elevated rates of melanoma (NEJM JW Gastroenterol Aug 24 2012) and NMSC (Clin Gastroenterol Hepatol 2010; 8:268) associated with their use.
In the current study, investigators assessed the risks for NMSC and other cancers using pooled data on 1594 patients with Crohn disease participating in clinical trials of adalimumab. Compared with the general population, patients receiving adalimumab monotherapy did not have a greater tha…